AXA partners with China Biotech Services

AXA has signed a Memorandum of Understanding with China Biotech Services to explore advanced cancer treatments, including Boron Neutron Capture Therapy (BNCT). The collaboration, involving AXA China Region Insurance and AXA International Reinsurance (Shanghai), aims to expand access to innovative therapies for cancer patients.

BNCT is a precision radiotherapy approach that targets tumor cells while minimizing damage to surrounding tissue. With growing incidence of head and neck cancers in regions like Hong Kong, the partnership seeks to diversify treatment options and improve outcomes for patients facing aggressive or recurrent malignancies.

“AXA remains deeply committed to a customer-first philosophy, offering comprehensive and high-quality medical protection tailored to individual needs. We continuously track healthcare trends and integrate cutting-edge medical solutions into our insurance plans to ensure our services remain relevant and impactful. We are delighted to collaborate with China Biotech Services to jointly explore innovative medical technologies and pharmaceuticals, further enhancing our insurance offerings and deliver exceptional health protection and a wide range of care options to customers in need. This collaboration underscores AXA’s dedication to providing excellent health protection and diversified medical solutions.” – Janet Lee, Chief Life and Health Insurance Officer, AXA Hong Kong and Macau .